The UK’s Purespring Therapeutics is one of the first gene therapy companies to focus on diseases of the kidney, and with ex-Sandoz CEO Richard Francis appointed Purespring’s CEO from 1 February, the emerging biotech is expected to move forward quickly with therapeutic candidates that it aims to take right to the market.
For Francis, who stepped down from Sandoz Pharmaceuticals Corp
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?